UBS AM’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $217 | Sell |
38
-233,710
| -100% | -$1.06M | ﹤0.01% | 3695 |
|
|
2026
Q1 | $1.05M | Buy |
233,748
+9,615
| +4% | +$50.1K | ﹤0.01% | 2331 |
|
|
2025
Q4 | $1.38M | Buy |
224,133
+23,260
| +12% | +$169K | ﹤0.01% | 2030 |
|
|
2025
Q3 | $1.45M | Sell |
200,873
-174,722
| -47% | -$1.04M | ﹤0.01% | 1874 |
|
|
2025
Q2 | $1.99M | Buy |
375,595
+76,339
| +26% | +$451K | ﹤0.01% | 2143 |
|
|
2025
Q1 | $2.65M | Buy |
299,256
+14,027
| +5% | +$168K | ﹤0.01% | 1862 |
|
|
2024
Q4 | $3.91M | Buy |
285,229
+86,973
| +44% | +$1.6M | ﹤0.01% | 1731 |
|
|
2024
Q3 | $5.43M | Buy |
198,256
+18,446
| +10% | +$499K | ﹤0.01% | 1530 |
|
|
2024
Q2 | $4.4M | Buy |
179,810
+86,439
| +93% | +$1.9M | ﹤0.01% | 1562 |
|
|
2024
Q1 | $1.99M | Hold |
93,371
| – | – | ﹤0.01% | 1698 |
|
|
2023
Q4 | $1.79M | Hold |
93,371
| – | – | ﹤0.01% | 1746 |
|
|
2023
Q3 | $1.5M | Buy |
93,371
+6,964
| +8% | +$133K | ﹤0.01% | 1759 |
|
|
2023
Q2 | $2.01M | Hold |
86,407
| – | – | ﹤0.01% | 1640 |
|
|
2023
Q1 | $2.01M | Buy |
86,407
+14,195
| +20% | +$288K | ﹤0.01% | 1640 |
|
|
2022
Q4 | $1.05M | Sell |
72,212
-2,546
| -3% | -$47.4K | ﹤0.01% | 1828 |
|
|
2022
Q3 | $1.43M | Sell |
74,758
-2,122
| -3% | -$48.7K | ﹤0.01% | 1769 |
|
|
2022
Q2 | $1.4M | Sell |
76,880
-30,547
| -28% | -$634K | ﹤0.01% | 1792 |
|
|
2022
Q1 | $2.71M | Sell |
107,427
-229
| -0.2% | -$5.86K | ﹤0.01% | 1633 |
|
|
2021
Q4 | $2.97M | Sell |
107,656
-4,021
| -4% | -$116K | ﹤0.01% | 1682 |
|
|
2021
Q3 | $3.61M | Buy |
111,677
+11,787
| +12% | +$391K | ﹤0.01% | 1520 |
|
|
2021
Q2 | $3.05M | Buy |
99,890
+19,082
| +24% | +$551K | ﹤0.01% | 1651 |
|
|
2021
Q1 | $2.46M | Buy |
80,808
+3,858
| +5% | +$109K | ﹤0.01% | 1672 |
|
|
2020
Q4 | $1.52M | Sell |
76,950
-2,884
| -4% | -$46.6K | ﹤0.01% | 1793 |
|
|
2020
Q3 | $1.04M | Hold |
79,834
| – | – | ﹤0.01% | 1834 |
|
|
2020
Q2 | $905K | Sell |
79,834
-13,943
| -15% | -$198K | ﹤0.01% | 1852 |
|
|
2020
Q1 | $1.34M | Sell |
93,777
-3,362
| -3% | -$71K | ﹤0.01% | 1582 |
|
|
2019
Q4 | $2.65M | Buy |
97,139
+1,623
| +2% | +$44.7K | ﹤0.01% | 1474 |
|
|
2019
Q3 | $2.73M | Buy |
95,516
+11,024
| +13% | +$321K | ﹤0.01% | 1467 |
|
|
2019
Q2 | $2.35M | Buy |
84,492
+11,576
| +16% | +$327K | ﹤0.01% | 1510 |
|
|
2019
Q1 | $2.42M | Buy |
72,916
+15,813
| +28% | +$481K | ﹤0.01% | 1428 |
|
|
2018
Q4 | $1.66M | Buy |
57,103
+8,616
| +18% | +$310K | ﹤0.01% | 1515 |
|
|
2018
Q3 | $2.23M | Buy |
48,487
+4,810
| +11% | +$214K | ﹤0.01% | 1458 |
|
|
2018
Q2 | $1.63M | Sell |
43,677
-8,251
| -16% | -$279K | ﹤0.01% | 1592 |
|
|
2018
Q1 | $1.53M | Buy |
51,928
+974
| +2% | +$33K | ﹤0.01% | 1586 |
|
|
2017
Q4 | $1.75M | Buy |
50,954
+2,615
| +5% | +$88.2K | ﹤0.01% | 1495 |
|
|
2017
Q3 | $1.75M | Buy |
48,339
+3,430
| +8% | +$97.8K | ﹤0.01% | 1461 |
|
|
2017
Q2 | $1.16M | Buy |
44,909
+10,545
| +31% | +$224K | ﹤0.01% | 1593 |
|
|
2017
Q1 | $660K | Buy |
34,364
+10,667
| +45% | +$189K | ﹤0.01% | 1778 |
|
|
2016
Q4 | $395K | Sell |
23,697
-20,600
| -47% | -$373K | ﹤0.01% | 1863 |
|
|
2016
Q3 | $912K | Sell |
44,297
-1,826
| -4% | -$46.3K | ﹤0.01% | 1720 |
|
|
2016
Q2 | $1.41M | Sell |
46,123
-53,197
| -54% | -$1.85M | ﹤0.01% | 1497 |
|
|
2016
Q1 | $3.72M | Sell |
99,320
-4,215
| -4% | -$159K | ﹤0.01% | 1116 |
|
|
2015
Q4 | $4.47M | Sell |
103,535
-9,095
| -8% | -$384K | 0.01% | 1110 |
|
|
2015
Q3 | $4.22M | Buy |
112,630
+9,079
| +9% | +$322K | ﹤0.01% | 1119 |
|
|
2015
Q2 | $3.52M | Sell |
103,551
-24,949
| -19% | -$848K | ﹤0.01% | 1169 |
|
|
2015
Q1 | $4.55M | Buy |
128,500
+25,100
| +24% | +$898K | ﹤0.01% | 1071 |
|
|
2014
Q4 | $3.52M | Sell |
103,400
-3,942
| -4% | -$140K | ﹤0.01% | 1131 |
|
|
2014
Q3 | $4.14M | Sell |
107,342
-2,600
| -2% | -$97K | ﹤0.01% | 1072 |
|
|
2014
Q2 | $4.28M | Sell |
109,942
-589,821
| -84% | -$21.9M | ﹤0.01% | 1076 |
|
|
2014
Q1 | $23.9M | Sell |
699,763
-13,641
| -2% | -$423K | 0.03% | 614 |
|
|
2013
Q4 | $15M | Buy |
713,404
+64,166
| +10% | +$1.62M | 0.02% | 713 |
|
|
2013
Q3 | $15.3M | Buy |
649,238
+259,200
| +66% | +$7.36M | 0.02% | 682 |
|
|
2013
Q2 | $10.5M | Buy |
+390,038
| New | +$11.3M | 0.01% | 751 |
|
Other funds holding MYGN
VPC
UBS AM's MYGN Position: Q2 2026 in Review
UBS AM reduced its Myriad Genetics (MYGN) stake by 100% in Q2 2026, selling an estimated $1.06M and leaving 38 shares worth $217. The position accounts for ﹤0.01% of the portfolio, ranked #3695.
UBS AM first reported a position in MYGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $23.9M in Q1 2014. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.
- UBS AM held 38 shares of Myriad Genetics worth $217 as of Q2 2026.
- UBS AM sold 233,710 Myriad Genetics shares in Q2 2026, an estimated $1.06M.
- Myriad Genetics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3695 holding.
- UBS AM first reported a position in Myriad Genetics in Q2 2013 and has held it in 53 quarters since.
- UBS AM's Myriad Genetics position peaked at $23.9M in Q1 2014.
- 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.